QURE — uniQure N.V. Stock Price, Chart & AI Report

Negative Apr 13, 2026 • 13:00 UTC GlobeNewswire Inc. • The Schall Law Firm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased uniQure N.V. securities between September 24, 2025, and October 31, 2025, for a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the timeline for its BLA submission, resulting in investor losses.

QURE securities fraud class action lawsuit FDA approval BLA timeline misleading statements investor losses shareholder rights

Sentiment note

The company is accused of making false and misleading statements to the market regarding FDA approval prospects and BLA timeline delays, resulting in material investor losses. These allegations of securities fraud and market deception warrant a negative sentiment rating.

Negative Apr 10, 2026 • 17:53 UTC GlobeNewswire Inc. • Hagens Berman

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorting comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.

QURE FDA criticism gene therapy securities class action regulatory misrepresentation AMT-130 study design stock decline

Sentiment note

The company faces serious allegations of misrepresenting FDA interactions, using unapproved study designs, and downplaying regulatory requirements. Public FDA criticism, a 49% stock decline, and an ongoing securities class action lawsuit indicate significant corporate governance and regulatory compliance failures.

Negative Apr 8, 2026 • 20:57 UTC GlobeNewswire Inc. • Hagens Berman

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorted comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.

QURE FDA criticism gene therapy securities class action regulatory misrepresentation AMT-130 stock decline investor losses

Sentiment note

Company faces serious allegations of misrepresenting FDA interactions, using unapproved study designs, and downplaying regulatory requirements. Public FDA criticism, 49% stock decline, and ongoing securities class action lawsuit indicate significant corporate governance and regulatory compliance failures.

Negative Apr 8, 2026 • 01:47 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

uniQure N.V. faces a securities fraud class action lawsuit after the FDA rejected the company's data for its lead drug candidate AMT-130, causing a 49% stock price decline from $67.69 to $34.29 on November 3, 2025. Investors who purchased shares between September 24 and October 31, 2025 can file lead plaintiff applications by April 13, 2026.

QURE securities fraud FDA approval delay class action lawsuit AMT-130 stock decline BLA submission material information disclosure

Sentiment note

Company faces securities fraud allegations for failing to disclose material information about FDA concerns regarding its lead drug candidate. Stock declined 49% following FDA approval delay announcement, indicating significant investor losses and loss of confidence in the company's drug development timeline.

Negative Apr 7, 2026 • 19:59 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, NuScale Power Corporation, and uniQure N.V. The AMC lawsuit concerns alleged securities fraud related to APE (Preferred Equity Units) holders being excluded from a special dividend due to a technical loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

AMC SMR QURE class action lawsuit securities fraud APE preferred equity units special dividend Certificate of Designations

Sentiment note

Company is subject to a class action lawsuit filed by Pomerantz LLP, indicating alleged investor losses and potential securities violations, though specific details are not provided in the excerpt.

Negative Apr 7, 2026 • 19:49 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE

Pomerantz Law Firm has filed class action lawsuits against uniQure N.V., AMC Entertainment Holdings, Inc., and NuScale Power Corporation on behalf of investors who suffered losses. The primary focus is on uniQure, which experienced a 49.34% stock price decline following FDA feedback that Phase I/II study data for its AMT-130 gene therapy may be inadequate for a Biologics License Application submission. Investors have until April 13, 2026, to request Lead Plaintiff status.

QURE AMC SMR class action lawsuit securities fraud FDA feedback gene therapy stock price decline

Sentiment note

Company faced significant regulatory setback with FDA indicating Phase I/II study data may be inadequate for BLA submission, resulting in 49.34% stock price decline and class action lawsuit for alleged securities fraud

Negative Apr 6, 2026 • 02:03 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOM

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. Trip.com Group Limited faces allegations of understating regulatory risks from monopolistic business activities. The firm is seeking lead plaintiffs with a May 11, 2026 deadline for Trip.com investors who purchased securities between April 30, 2024 and January 13, 2026.

TCOM HCXY HTGC QURE securities class action lead plaintiff deadline Trip.com Group Limited Hercules Capital

Sentiment note

Company is defendant in a securities class action lawsuit with a specific focus on investors with losses exceeding $100,000, indicating material investor harm.

Negative Apr 6, 2026 • 01:32 UTC GlobeNewswire Inc. • Rosen Law Firm

UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

Rosen Law Firm is notifying investors in uniQure N.V., Inovio Pharmaceuticals, and Masonite International Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. uniQure faces allegations of misrepresenting FDA approval status of its Pivotal Study and downplaying delays to its Biologics License Application timeline. Investors with losses exceeding $100K are encouraged to seek counsel before the respective deadlines.

QURE INO securities class action lead plaintiff deadline FDA approval Biologics License Application investor losses pharmaceutical litigation

Sentiment note

Company is defendant in securities class action lawsuit alleging misrepresentation regarding FDA approval status of clinical study and failure to disclose likelihood of BLA submission delays, resulting in investor losses.

Negative Apr 6, 2026 • 01:27 UTC GlobeNewswire Inc. • Rosen Law Firm

INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

Rosen Law Firm is notifying investors in Inovio Pharmaceuticals, uniQure N.V., and Masonite International Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. Inovio faces allegations of false statements regarding manufacturing deficiencies and overstated regulatory prospects for its INO-3107 product. Investors with losses exceeding $100K are encouraged to seek counsel before the respective deadlines.

INO QURE securities class action lead plaintiff deadline false statements manufacturing deficiency regulatory approval investor losses

Sentiment note

Company is subject to a securities class action lawsuit with an April 13 deadline, indicating alleged investor losses and legal disputes, though specific allegations are not detailed in the provided excerpt.

Negative Apr 4, 2026 • 15:19 UTC GlobeNewswire Inc. • Hagens Berman

QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Hagens Berman is investigating uniQure N.V. following FDA officials' public rebukes alleging the company misrepresented its interactions with the FDA and used an unapproved study design for its gene therapy candidate AMT-130. The FDA disputed uniQure's claims about sham surgery requirements and the use of external historical data as a control. A securities class action lawsuit covers investors who purchased shares between September 24 and October 31, 2025, with an April 13, 2026 deadline to become Lead Plaintiff.

QURE FDA rebuke gene therapy securities class action misleading statements clinical trial design stock decline regulatory approval

Sentiment note

The company faces serious allegations of misrepresenting FDA interactions and using unapproved study designs. Public FDA rebukes, a 49% stock drop following disclosure of lack of FDA agreement, and an ongoing securities class action lawsuit indicate significant regulatory and legal challenges that undermine investor confidence.

Negative Apr 2, 2026 • 22:39 UTC GlobeNewswire Inc. • Rosen Law Firm

UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

A securities class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting and failing to disclose issues with its Pivotal Study design and FDA approval status for its Huntington's Disease drug candidate. The lawsuit claims defendants downplayed the likelihood of delays to the Biologics License Application timeline. Investors who purchased shares between September 24, 2025 and October 31, 2025 have until April 13, 2026 to serve as lead plaintiff.

QURE securities class action misrepresentation FDA approval Pivotal Study Biologics License Application Huntington's Disease lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding FDA approval status of its pivotal study and downplaying of BLA submission delays. These allegations suggest investor losses and regulatory/clinical setbacks for the company's lead drug candidate.

Negative Apr 2, 2026 • 21:51 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th

A class action lawsuit has been filed against uniQure N.V. for allegedly making materially false and misleading statements regarding its Pivotal Study FDA approval and BLA timeline delays. Investors who purchased shares between September 24, 2025, and October 31, 2025, have until April 13, 2026, to apply as lead plaintiff.

QURE class action lawsuit securities fraud misleading statements FDA approval BLA submission Pivotal Study investor losses

Sentiment note

The company is accused of making materially false and misleading statements about its Pivotal Study FDA approval status and failing to disclose the likelihood of BLA timeline delays. These allegations of securities fraud and lack of reasonable basis for business statements indicate serious corporate governance and disclosure issues that resulted in investor losses.